Hormonal
GLP-1 receptor agonists (GLP-1RAs) and dual GLP-1/GIP receptor agonists (e.g., tirzepatide) significantly reduce body weight and improve glycemic control in patients with type 2 diabetes and obesity by stimulating insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite.
For individuals with obesity or type 2 diabetes, GLP-1 and GLP-1/GIP receptor agonists are highly effective treatments that promote significant weight loss and improve blood sugar control. These medications work by mimicking natural hormones to increase insulin, reduce glucagon, slow digestion, and decrease appetite. While they can cause gastrointestinal side effects like nausea, starting with a low dose and increasing it slowly helps manage these symptoms. They are particularly beneficial for those who have not achieved sufficient weight loss or cardiovascular risk reduction with lifestyle changes alone.
GLP-1RAs exert their effects by stimulating insulin secretion, suppressing glucagon release, delaying gastric emptying, and reducing appetite through the activation of the GLP-1 receptor. These agents have demonstrated significant efficacy in the management of type 2 diabetes mellitus (T2DM) and obesity.
Why this rating
The claim is supported by a comprehensive review of multiple randomized controlled trials, network meta-analyses, and large-scale cardiovascular outcome trials.
Source
The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review
Zhao Liu et al. · Drug Design Development and Therapy · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →